|
|
|
|
|
|
|
Backward Thinking
|
|
Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT
Paris, France, 4th May 2022 - Coave Therapeutics (‘Coave’), a
clinical-stage biotechnology company focused on developing life-changing
gene therapies for CNS (Central Nervous System) and eye diseases, today
announced that research on its AAV-Ligand Conjugates platform
(ALIGATER) will be presented at the 2022 American Society of Cell &
Gene Therapy (ASCGT) meeting, which will be held virtually and in person
in Washington, D.C., 16 to 19 May.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
|
|
